SMLR Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Securities Fraud Class Action Against Semler Scientific, Inc.

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - Semler Scientific is accused of not disclosing an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - The company received an initial civil investigative demand (CID) from the DOJ in July 2017, which investigated whether it violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - On February 11, 2025, Semler Scientific engaged in unsuccessful settlement discussions with the DOJ, raising concerns about a potential lawsuit [3]. Group 2: Financial Impact - Following the revelation of the investigation on February 28, 2025, Semler Scientific's stock price dropped by $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. - After the company announced a settlement agreement with the DOJ for $29.75 million on April 15, 2025, the stock fell by $3.40, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery, and they can remain absent class members if they choose [5].